Informace o publikaci

Immunomodulatory Agents for Multiple Myeloma

Autoři

MINAŘÍK Jiří ŠEVČÍKOVÁ Sabina

Rok publikování 2022
Druh Článek v odborném periodiku (nerecenzovaný)
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
Popis The treatment of multiple myeloma (MM) has undergone a significant paradigm shift in the last 20 years, from conventional chemotherapy to more tumor-specific treatments, based on the interference with pathogenesis of the malignant clone as well as the bone microenvironment. Indeed, the introduction of novel drugs with “biological mechanisms of action” into MM treatment has established a worldwide trend towards chemotherapy-free regimens with lower toxicity (or significantly different toxic profiles) and targeted mechanisms of action. Immunomodulatory drugs (IMiDs) represent the cornerstone of the evolution of novel therapy in MM.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info